Table 2.
Characteristics of first line systemic therapy postshort course radiotherapy and response rates
| Characteristics | n (percentage where applicable) |
|---|---|
| Chemotherapeutic regimen | |
| CAPOX | 74 (70.5) |
| FOLFIRINOX | 11 (10.5) |
| FOLFIRI | 9 (8.6) |
| FOLFOX | 6 (5.7) |
| Capecitabine | 5 (4.8) |
| Targeted therapy (with chemotherapy backbone) | |
| Bevacizumab | 29 (27.6) |
| Cetuximab | 24.(5) |
| Grade 3 and 4 toxicities | |
| Hematological | 4 (4) |
| Vomiting | 4 (4) |
| Diarrhoea | 17 (16.2) |
| Hand foot syndrome (Grade 2 and Grade 3) | 11 (10.5) |
| Fatigue (Grade 3) | 2 (1.3) |
| Response rates in primary | |
| CR | 3 (2.9) |
| PR | 38 (36.2) |
| SD | 31 (29.5) |
| PD | 27 (25.7) |
| RR | 41 (39.1) |
| DCR | 72 (68.6) |
| Not evaluated | 4 (3.8) |
| Lost to follow-up | 2 (1.9) |
| Response rates in metastatic sites | |
| Complete response | 2 (1.9) |
| Partial response | 27 (25.7) |
| Stable disease | 25 (23.8) |
| Progressive disease | 43 (41.0) |
| Response rates | 29 (27.6) |
| DCR | 54 (51.4) |
| Not available | 6 (5.6) |
| Lost to follow-up | 2 (2.0) |
CAPOX=Capecitabine-oxaliplatin, FOLFIRINOX=Fluorouracil-leucovorin-irinotecan-oxaliplatin, FOLFIRI=Fluorouracil-leucovorin-irinotecan, FOLFOX=Fluorouracil plus oxaliplatin, CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease, RR=Response rates, DCR=Disease control rate